Cogent Biosciences, Inc. has signed a 31,518-square-foot lease at 180 CityPoint, a Class A office and life sciences building owned and operated by BXP in Waltham, MA. Cogent’s new space will serve as the company’s corporate headquarters in a relocation from 275 Wyman St. as it prepares to commercialize its first product.
Cushman & Wakefield’s Michael O’Leary, Kevin McNamara, Thomas Ashe and Ross Gaudet represented Cogent Biosciences. BXP was self-represented by Pat Mulvihill, SVP of leasing, and Casey Torto, leasing manager for BXP’s Boston region.
“This headquarters lease underscores the shift of innovative biotech companies coming to Waltham, which offers the high-quality space and accessibility that companies primarily once looked for in Cambridge,” said McNamara. “Cogent will benefit from a state-of-the-art environment that supports the firm’s culture, recruitment and long-term success.”
BXP recently signed Amplitude Vascular Systems at 180 CityPoint, which will relocate from the Seaport District into 38,000 square feet in Waltham.
The post Cogent Biosciences Relocates Headquarters to BXP’s 180 CityPoint appeared first on Connect CRE.